- Home
- LITE vs IONS Comparison
LITE vs IONS Comparison
Compare LITE & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITE
- IONS
- Stock Information
- Founded
- LITE 2015
- IONS 1989
- Country
- LITE United States
- IONS United States
- Employees
- LITE N/A
- IONS N/A
- Industry
- LITE Telecommunications Equipment
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- LITE Telecommunications
- IONS Health Care
- Exchange
- LITE Nasdaq
- IONS Nasdaq
- Market Cap
- LITE 5.7B
- IONS 5.9B
- IPO Year
- LITE N/A
- IONS 1991
- Fundamental
- Price
- LITE $94.85
- IONS $39.62
- Analyst Decision
- LITE Buy
- IONS Buy
- Analyst Count
- LITE 15
- IONS 17
- Target Price
- LITE $82.47
- IONS $57.59
- AVG Volume (30 Days)
- LITE 2.1M
- IONS 1.7M
- Earning Date
- LITE 08-13-2025
- IONS 07-31-2025
- Dividend Yield
- LITE N/A
- IONS N/A
- EPS Growth
- LITE N/A
- IONS N/A
- EPS
- LITE N/A
- IONS N/A
- Revenue
- LITE $1,472,600,000.00
- IONS $717,253,000.00
- Revenue This Year
- LITE $21.98
- IONS $7.98
- Revenue Next Year
- LITE $31.42
- IONS $16.09
- P/E Ratio
- LITE N/A
- IONS N/A
- Revenue Growth
- LITE 3.58
- IONS N/A
- 52 Week Low
- LITE $38.29
- IONS $23.95
- 52 Week High
- LITE $104.00
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- LITE 77.94
- IONS 75.33
- Support Level
- LITE $86.63
- IONS $34.78
- Resistance Level
- LITE $90.65
- IONS $37.54
- Average True Range (ATR)
- LITE 3.11
- IONS 1.19
- MACD
- LITE 0.50
- IONS 0.33
- Stochastic Oscillator
- LITE 88.78
- IONS 85.91
About LITE Lumentum Holdings Inc.
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.